Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Tempest Therapeutics, Inc. amended First Amendment to Loan and Security Agreement with Oxford Finance LLC, as collateral agent, and certain additional lenders valued at $5.0 million (effective 2022-12-23).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Oxford Finance LLC, as collateral agent, and certain additional lenders
- Value
- $5.0 million
- Effective
- 2022-12-23
Exact text from the filing
On December 23, 2022, Tempest Therapeutics, Inc. (the “ Company ”) entered into a First Amendment to Loan and Security Agreement (the “ LSA Amendment ”), which modified that certain Loan and Security Agreement dated as of January 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “ Loan Agreement ”) by and among TempestTX, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ TempestTX ”), Oxford Finance LLC (the “ Lender ”), as collateral agent, and certain additional lenders party thereto from time to time. Pursuant to the LSA Amendment, (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Millendo ”), were joined as co-borrowers under the Loan Agreement, (ii) the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances), and (iii) a sec
View on SEC.gov